ASML vs IBEX

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.

IBEX exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial stability and operational efficiency. The stock is currently trading at $27.49, which is essentially at its Graham Number ($27.9) and significantly below its growth-based intrinsic value of $88.79. Despite a bearish technical trend and recent insider selling by the CEO, the combination of a low P/E (9.13), high ROE (33.65%), and robust earnings growth (45.6% YoY) presents a compelling value opportunity.